Huntington Disease – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23025IDB-L5

Select Item

Empower your strategies with our Huntington Disease – Drugs In Development, 2024 report and make more profitable business decisions.

Huntington’s disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow.

The Huntington Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Huntington Disease and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Huntington Disease
Key Targets
· Huntingtin; Synaptic Vesicular Amine Transporter; Caspase 6; Glutamate Ionotropic Receptor NMDA Type Subunit; Histone Deacetylase 2; Glucagon Like Peptide 1 Receptor; C5a Anaphylatoxin Chemotactic Receptor 1; D2 Dopamine Receptor; Cannabinoid Receptor 1; and Cannabinoid Receptor 2
Key Mechanisms of Action
· Huntingtin Inhibitor; Caspase 6 Inhibitor; Synaptic Vesicular Amine Transporter Inhibitor; Sigma Non Opioid Intracellular Receptor 1 Agonist; Peroxisome Proliferator Activated Receptor Gamma Agonist; NAD Dependent Protein Deacetylase Sirtuin 2 Inhibitor; Nuclear Factor Erythroid 2 Related Factor 2 Activator; Transitional Endoplasmic Reticulum ATPase Inhibitor; D2 Dopamine Receptor Antagonist; and C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist
Key Routes of Administration
· Oral; Intravenous; Intrathecal; Subcutaneous; Buccal; Intracerebral; Parenteral; Ophthalmic; Intramuscular; and Topical
Key Molecule Types
· Small Molecule; Gene Therapy; Cell Therapy; Antisense Oligonucleotide; Oligonucleotide; Synthetic Peptide; Antisense RNAi Oligonucleotide; Monoclonal Antibody; Peptide; and Gene-Modified Cell Therapy
Major Companies
· Medesis Pharma SA; Luye Pharma Group Ltd; IPS Bio Co Ltd; F. Hoffmann-La Roche Ltd; Caladria Therapeutics Inc; AFFiRiS AG; AbbVie Inc; Asklepios BioPharmaceutical Inc; Origami Therapeutics Inc; and PTC Therapeutics Inc

Scope

  • Therapeutics in Development: Covering 186 molecules, with 155 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Huntington Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Huntington Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Huntington Disease treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

AbbVie Inc
Academia Sinica
Acahealth Pharma and Biotech Co Ltd
Acen Regenerative Medicine Sci-Tech Co Ltd
Advantx Pharmaceuticals Inc
Aeton Therapeutics Inc
AFFiRiS AG
Alchemab Therapeutics Ltd
Alkermes Plc
Alnylam Pharmaceuticals Inc
Alsonex Pty Ltd
Anima Biotech Inc
ANLBio Co Ltd
Annexon Inc
Annji Pharmaceutical Co Ltd
AOP Health
ArunA Bio Inc
Arvinas Inc
Asdera LLC
Asklepios BioPharmaceutical Inc
Astellas Pharma Inc
Atalanta Therapeutics Inc
Avergen Pharmaceuticals GmbH
Azevan Pharmaceuticals Inc
Beijing Joekai Biotechnology Co Ltd
Biogen Inc
Bionaut Labs Inc
Biorchestra Co Ltd
Blade Therapeutics Inc
BPGbio Inc
BrainStorm Cell Therapeutics Inc
Caladria Therapeutics Inc
Cardiff University
Cellavita Pesquisa Cientifica Ltda
Centre for Drug Design and Discovery
Centre for Genomic Regulation
Ceptur Therapeutics Inc
Chaperone Pharma BV
Chaperone Therapeutics Inc
Children's Hospital of Philadelphia
Chong Kun Dang Pharmaceutical Corp.
Chugai Pharmaceutical Co Ltd
Cleave Therapeutics Inc
Collaborative Medicinal Development LLC
DanPET AB
Eikonoklastes Therapeutics Inc
Epinogen Co Ltd
ethris GmbH
Exicure Inc
Exopharm Ltd
ExoRNA Bioscience Nanjing Co Ltd
F. Hoffmann-La Roche Ltd
Forest Hills Partners Hong Kong Ltd
Fundamental Pharma Gmbh
Gatehouse Bio
Harness Therapeutics
Helmholtz Center Munich German Research Center for Health and Environment GmbH
HuidaGene Therapeutics Co Ltd
Immungenetics AG
Imperial College London
Incisive Genetics Inc
InnoMedica Holding AG
IPS Bio Co Ltd
Janusq LLC
Karolinska Institute
KeifeRx LLC
Krisani Bio Sciences Pvt Ltd
Life Edit Therapeutics Inc
Locanabio Inc
Loqus23 Therapeutics Ltd
Luye Pharma Group Ltd
Malachite Innovations Inc
Massachusetts General Hospital
MassGeneral Institute for Neurodegenerative Disorders
Medesis Pharma SA
Medibiofarma SL
MindImmune Therapeutics Inc
Mitochon Pharmaceuticals Inc
Mitochondria In Motion Inc
Mitoconix Bio Ltd
MitoRx Therapeutics Ltd
MMJ International Holdings Corp
Monash University
National Institute of Neurological Disorders and Stroke
NeuExcell Therapeutics Inc
Neurano Bioscience
Neurimmune Holding AG
Neurodon LLC
NeuroNascent Inc
Neuropore Therapies Inc
NeuroTau Inc
Neuvivo Inc
Nevrox Ltd
New World Laboratories Inc
Nomax Therapeutics Inc
Nuredis Inc
Ophidion Inc
Origami Therapeutics Inc
Oryzon Genomics SA
Oxalys Pharmaceuticals Inc
Paramag Biosciences
Passage Bio Inc
Pfizer Inc
PharmatrophiX Inc
PolyCore Therapeutics LLC
Priavoid GmbH
Prilenia Therapeutics Development Ltd
Primary Peptides Inc
Prime Medicine Inc
ProMIS Neurosciences Inc
ProQR Therapeutics NV
Prous Institute for Biomedical Research SA
PTC Therapeutics Inc
PurMinds NeuroPharma Inc
reMYND NV
ReNeuron Group Plc
Resilio Therapeutics LLC
ResQ Biotech
Retrotope Inc
RIKEN
Rumi Scientific Inc
S M Discovery Group LLC
Sage Therapeutics Inc
Salk Institute for Biological Studies
Sana Biotechnology Inc
Seelos Therapeutics
Inc.
Seneb BioSciences Inc
Shanghai BDgene Therapeutics Co Ltd
Shinkei Therapeutics LLC
Skyhawk Therapeutics Inc
SOLA Biosciences LLC
SOM Biotech SL
Spark Therapeutics Inc
Stealth BioTherapeutics Inc.
Suven Life Sciences Ltd
T3D Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Teitur Trophics ApS
Tel Aviv University
Teva Pharmaceutical Industries Ltd
Trailhead Biosystems Inc
TreeFrog Therapeutics SAS
Triplet Therapeutics Inc
U.S. National Institutes of Health
UCB SA
UniQure NV
University of Alberta
University of California Davis
University of California Irvine
University of Gdansk
University of Kansas
University of Massachusetts Amherst
University of Michigan
University of Strasbourg
University of Wisconsin Madison
Vanqua Bio Inc
VectorY Therapeutics Inc
Vico Therapeutics BV
Vivoryon Therapeutics NV
Voyager Therapeutics Inc
VX3 (DE) LP
Vybion Inc
Washington University in St Louis
Wave Life Sciences Ltd
Weizmann Institute of Science
Woolsey Pharmaceuticals Inc
ZyVersa Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Huntington Disease reports
Pharmaceuticals
New
Venture Capital Investment Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Merger and Acquisition Trends in Pharma - Q2 2026
$795 | July 2026
Pharmaceuticals
New
Emerging Market Outsourcing Report, Q2 2026
$2,950 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Huntington Disease – Drugs In Development, 2024 in real time.

  • Access a live Huntington Disease – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more